← Russell 3000 cross-section

CDNA CareDx, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$2.7bn
Revenue TTM
$458m
Net income TTM
$111m
Free cash flow
Composite score
71.5
Sector rank
#1453

Valuation

P / E
24.7
EV / EBITDA
19.4
EV / sales
5.2
FCF yield
Earnings yield vs 10-yr
-0.69pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
24.2%
EBITDA margin
26.8%
ROE
26.1%
ROIC
208.1%
Revenue growth
34.4%

Insider activity, last 90 days

Net open-market
$-11.92m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Testing Services Revenue Our testing services revenue is derived from AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung tests, which represented 76% and 77% of our total revenue for each of the three and six months ended June 30, 2026, respectively, and 72% of our total revenue for each of the three and six months ended June 30, 2025. Product Revenue Our product revenue is derived primarily from sales of AlloSeq Tx, Olerup SSP and QTYPE products. Product revenue represented 10% and 9% of our total revenue for the three and six months ended June 30, 2026, respectively, and 14% and 13% of our total revenue for the three and six months ended June 30, 2025, respectively. …CareDx, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →